Effect of Azithromycin on Myocardial Resistance to Ischemia/Reperfusion in Systemic Inflammatory Response Syndrome and Alimentary Obesity

Bull Exp Biol Med. 2021 Mar;170(5):613-617. doi: 10.1007/s10517-021-05117-3. Epub 2021 Mar 31.

Abstract

The study focuses on the effects of azithromycin on severity of ischemia/reperfusion myocardial injury during simulated systemic inflammatory response syndrome (SIRS) in primary visceral obesity (PVO). Total ischemia/reperfusion was modeled by Langendorff perfusion of isolated heart with following estimation of the size of myocardial infarction. SIRS was accompanied by an increase in blood levels of proinflammatory cytokines and LPS. Combination of PVO and SIRS produced no significant changes in the infarct size compared to the control. Administration of azithromycin to rats with PVO and SIRS resulted in pronounced alterations of biochemical and immunological parameters, although it did not affect the infarct size. In contrast, the use of tetracycline increased the size of myocardial infarction. This phenomenon should be taken into consideration in antimicrobial therapy.

Keywords: antimicrobial agents; infarct size; ischemia; isolated heart.

MeSH terms

  • Animals
  • Azithromycin / therapeutic use*
  • Cytokines / blood
  • Lipopolysaccharides / blood
  • Male
  • Myocardial Infarction / blood
  • Myocardial Infarction / drug therapy*
  • Myocardial Reperfusion Injury / drug therapy*
  • Obesity / blood
  • Obesity / drug therapy*
  • Obesity, Abdominal / blood
  • Obesity, Abdominal / drug therapy*
  • Rats
  • Systemic Inflammatory Response Syndrome / blood
  • Systemic Inflammatory Response Syndrome / drug therapy*

Substances

  • Cytokines
  • Lipopolysaccharides
  • Azithromycin